Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

PHASE3CompletedINTERVENTIONAL

Enrollment

614

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

November 22, 2024

Study Completion Date

November 26, 2024

Conditions

Complicated Urinary Tract InfectionAcute PyelonephritiscUTIAP

Interventions

DRUG

co-administration of cefepime and nacubactam

2 g cefepime and 1 g nacubactam

DRUG

co-administration of aztreonam and nacubactam

2 g aztreonama and 1 g nacubactam

DRUG

imipenem/cilastatin

1 g imipenem/1 g cilastatin

Trial Locations (1)

Meiji Research Site, Meegomäe